Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

The article highlights oral presentations reporting Phase 2 vision-protection outcomes and states that the Phase 3 trial has enrolled a patient population consistent with the Phase 2 cohort. Management positions the Phase 3 population as well suited to replicate prior vision outcomes, but no efficacy data, enrollment totals, timelines, or financial figures were disclosed.